Tag Archives: GLP-1 receptor agonist

The rise of oral GLP-1 medications is changing how clinicians approach type 2 diabetes treatment. But what if one of the biggest barriers, strict dosing requirements, suddenly disappeared? A newly approved oral option without food or water restrictions is making that question very real. As a result, clinicians now have …

Could taking a pill instead of an injection change how early people begin treatment for type 2 diabetes or obesity? In 2026, these oral GLP-1 medications are gaining attention for their simplified dosing and improved convenience. As newer formulations reduce traditional barriers, clinicians are beginning to rethink when to initiate …

Oral GLP-1 therapy is quickly reshaping how we treat type 2 diabetes, especially for patients who hesitate at the thought of injections. For years, glucagon-like peptide-1 receptor agonists were only available as injectables such as semaglutide and dulaglutide. However, the introduction of semaglutide tablets and the development of higher-dose oral …

Nonalcoholic steatohepatitis (NASH) and metabolic dysfunction–associated steatotic liver disease (MASLD) are rapidly becoming leading causes of chronic liver disease worldwide. Traditionally, clinicians have associated MASLD with obesity, insulin resistance, and type 2 diabetes, often using body mass index (BMI) and A1C as screening triggers. However, an important shift is occurring …

The arrival of oral GLP‑1 therapy for type 2 diabetes marks a pivotal shift in diabetes care. Traditionally available only as injections, GLP‑1 receptor agonists have shown impressive results in lowering blood glucose, aiding in weight loss, and protecting the heart. Now, oral versions like semaglutide are removing barriers for …

Managing type 2 diabetes in people with advanced chronic kidney disease (CKD) and end-stage kidney disease (ESKD) on dialysis presents unique clinical challenges. With the 2026 Standards of Care increasingly shifting the focus toward cardio-renal outcomes, many clinicians are asking: how far can we go safely with GLP‑1 receptor agonists …